MolMed: New Phase II Data on Investigational Drug NGR-hTNF Presented at ASCO – MarketWatch (press release)
MolMed: New Phase II Data on Investigational Drug NGR-hTNF Presented at ASCOMarketWatch (press release)… II clinical trials of its investigational drug NGR-hTNF in as many different types of solid tumours, together with an update on the clinical deve…
